Molecular Tumor Boards: Realizing Precision Oncology Therapy

Technological advances in high‐throughput next‐generation sequencing (NGS) along with advances in computational processes have brought about the dawn of the genomic medicine era. NGS has enabled molecular characterization of malignancies, and facilitated the development and approval of gene‐ and imm...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2018-02, Vol.103 (2), p.206-209
Main Authors: Patel, Maulik, Kato, Shumei M., Kurzrock, Razelle
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Technological advances in high‐throughput next‐generation sequencing (NGS) along with advances in computational processes have brought about the dawn of the genomic medicine era. NGS has enabled molecular characterization of malignancies, and facilitated the development and approval of gene‐ and immune‐targeted therapies, both of which impact the mutanome. Clinical implementation of this technology, approval of novel targeted agents, and establishment of molecular tumor boards has enabled precision oncology to become a reality.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.920